Studieoverzicht
BOOG nr.: |
Status: ( View all )
|
Indication: ( Advanced/metastatic )
|
Subindication: |
Menopausal status: |
2022-03 ALPHABET | Open | Advanced/metastatic | HER2+, any HR | Both pre- and postmenopausal | ||||||||||||||
2021-04 TROPION-Breast01 | Active, not recruiting | Advanced/metastatic | HER2- HR+ | Both pre- and postmenopausal | ||||||||||||||
2021-03 EMBER-3 | Active, not recruiting | Advanced/metastatic | HER2- HR+ | Both pre- and postmenopausal | ||||||||||||||
2021-01 SEQUEL-Breast | Open | Advanced/metastatic | HER2- HR+ | Both pre- and postmenopausal | ||||||||||||||
2020-02 AMEERA-5 | Active, not recruiting | Advanced/metastatic | HER2- HR+ | Both pre- and postmenopausal | ||||||||||||||
2020-01 DESTINY-Breast 06 | Active, not recruiting | Advanced/metastatic | Any HER2, HR+ | Both pre- and postmenopausal | ||||||||||||||
2019-01 TIBET | Active, not recruiting | Advanced/metastatic | HER2- HR+ | Both pre- and postmenopausal | ||||||||||||||
2017-04 BYLieve | Follow up | Advanced/metastatic | HER2- HR+ | Not applicable | ||||||||||||||
2017-03 SONIA | Active, not recruiting | Advanced/metastatic | HER2- HR+ | Not applicable | ||||||||||||||
2015-02 MonaLEEsa-3 | Follow up | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2015-01 Monarch-3 | Follow up | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2014-02 BRAVO | Follow up | Advanced/metastatic | HER2-, any HR | Both pre- and postmenopausal | ||||||||||||||
2014-01 MONALEESA-2 | Closed | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2013-06 Biomarker Study Everolimus | Closed | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2013-05 BELLE-3 | Follow up | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2013-03 PERNETTA | Closed | Advanced/metastatic | HER2+, any HR | Both pre- and postmenopausal | ||||||||||||||
2013-01 TRIPLE-B | Active, not recruiting | Advanced/metastatic | TNBC | Both pre- and postmenopausal | ||||||||||||||
2012-01 BALLET | Closed | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2011-01 Abiraterone | Follow up | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2010-05 SUBMIT | Closed | Advanced/metastatic | Any HER2, any HR | Both pre- and postmenopausal | ||||||||||||||
2010-02 STOP&GO | Closed | Advanced/metastatic | HER2-, any HR | Both pre- and postmenopausal | ||||||||||||||
2009-05 BOLERO 2 | Closed | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2008-03 HAT | Closed | Advanced/metastatic | HER2+, any HR | Both pre- and postmenopausal | ||||||||||||||
2008-02 A6181099 | Closed | Advanced/metastatic | Any HER2, any HR | Both pre- and postmenopausal | ||||||||||||||
2006-06 ATX | Closed | Advanced/metastatic | HER2-, any HR | Both pre- and postmenopausal | ||||||||||||||
2006-02 OMEGA | Closed | Advanced/metastatic | Any HER2, any HR | Postmenopausal | ||||||||||||||
2004-02 TBP | Closed | Advanced/metastatic | HER2+, any HR | Both pre- and postmenopausal | ||||||||||||||
2002-02 Hertax | Closed | Advanced/metastatic | HER2+, any HR | Both pre- and postmenopausal |